Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients

• Published in: European review for medical and pharmacological sciences Vol. 27; no. 24; p. 11988
• Main Authors: Yan, C-Q, Liang, C, Lan, Z-R, Su, C, Xiong, S-Y, Yang, Y-X, Chen, J-M, Tang, S-L, Huang, J-S, Zhang, Z-H, Luo, M-J, Xiao, Z-H
• Format: Journal Article
• Language: English
• Published: Italy 01.12.2023
• Subjects: Allopurinol - therapeutic use; Benzbromarone - therapeutic use; Chemical and Drug Induced Liver Injury - drug therapy; China; Febuxostat - therapeutic use; Gout - drug therapy; Gout Suppressants - therapeutic use; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Uricosuric Agents - therapeutic use; China
• ISSN: 2284-0729
• DOI: 10.26355/eurrev_202312_34797

Febuxostat and benzbromarone are two common drugs for the treatment of gout, but the clinical efficacy of these two drugs is controversial. This meta-analysis aimed to compare the efficacy of febuxostat and benzbromarone in the treatment of gout. PubMed, Embase, and the Cochrane Library were searched for articles related to febuxostat and benzbromarone in the treatment of gout from inception to January 7, 2023. Titles and abstracts were reviewed in accordance with predesigned inclusion and exclusion criteria, and data were extracted independently. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the studies, and the continuous variables were expressed as the standard mean square error (SMD) by STATA 16 (Stata Corp., College Station, TX, USA). The sensitivity analysis was conducted by randomly removing a study, and the heterogeneity was analyzed by funnel plots and Egger's test. According to the search strategy, a total of 1,043 publications were retrieved from the three aforementioned databases, of which 45 publications were excluded due to duplication. Fourteen studies remained after screening titles and abstracts, and a total of 7 studies met the inclusion criteria after a comprehensive evaluation of the 14 studies. Meta-analysis showed that the uric acid (UA)-reducing effect of febuxostat is better than that of benzbromarone, while febuxostat showed a better ability to improve the estimated glomerular filtration rate (eGFR) and reduce Cr and blood urea nitrogen (BUN). In terms of hepatotoxicity, benzbromarone was not as potent as febuxostat in increasing alanine transaminase (ALT) and aspartate transaminase (AST), suggesting that benzbromarone has less hepatotoxicity. Moreover, there was no significant difference in the effect on blood lipid levels between the two drugs. The beneficial effect of febuxostat on renal function-related indexes such as the eGFR, Cr and BUN is significant, while benzbromarone is more effective in reducing UA and has relatively less hepatotoxicity. The specific efficacy of the two drugs needs to be confirmed by further research.